Author: Bill Snyder
Reduced kidney function may cause cardiovascular disease: study
Dec. 15, 2022—An international team of investigators has found that mild to moderate reduction in kidney function may cause cardiovascular disease, even in people without symptoms of heart disease or diabetes.
Nephrology society lauds Bock’s research on kidney development
Dec. 15, 2022—Vanderbilt's Fabian Bock, MD, PhD, won two awards at the Basic Research Forum for Emerging Kidney Scientists, presented virtually by the American Society of Nephrology and American Physiological Society.
VUMC well represented at Association of American Medical Colleges annual meeting
Dec. 14, 2022—Several Vanderbilt University Medical Center faculty were featured in the annual meeting of the Association of American Medical Colleges in Nashville.
Grants spur efforts to create molecular ‘atlases’ of organs
Nov. 17, 2022—Vanderbilt researchers have received three grants totaling $13.6 million from the National Institutes of Health to develop molecular “atlases” of the brain, kidney, eye and other tissues.
Several from VUMC among most highly cited researchers
Nov. 17, 2022—Nine current faculty members of the Vanderbilt University School of Medicine have made this year’s list of scientists whose papers have been cited most frequently by other researchers.
Department of Psychiatry and Behavioral Sciences celebrates 75 years
Nov. 14, 2022—The Department of Psychiatry and Behavioral Sciences celebrated its 75th anniversary on Nov. 11 with an afternoon program that highlighted its contributions to professional education, research, and clinical care.
Gastric Cancer Foundation funds Eunyoung Choi research
Nov. 10, 2022—The Gastric Cancer Foundation has awarded a one-year $100,000 research grant to Eunyoung Choi, PhD, to support her efforts to find a way to disrupt the transformation of dysplastic stem cells into stomach cancer.
AstraZeneca VP to discuss COVID-19 collaboration with VUMC Nov. 17
Nov. 10, 2022—On Thursday, Nov. 17, Mark Esser, PhD, vice president, Early Vaccines and Immune Therapies R&D at AstraZeneca, will discuss his company’s collaboration with Vanderbilt University Medical Center that led to development of the Evusheld antibody combo to prevent COVID-19 in high-risk individuals.
Hawiger still blazing a trail in inflammation research
Nov. 10, 2022—Vanderbilt research describes a new investigational peptide drug that can penetrate immune and nonimmune cells, and block inflammatory signaling in a preclinical model of atopic dermatitis — eczema.
Study defines role of steroids in congenital heart disease surgery
Nov. 10, 2022—Steroids are commonly given to infants during open-heart surgery to reduce inflammation, but whether the drugs significantly improve patient outcomes has not been settled — until now.
Study finds Moderna’s COVID-19 vaccine safe and effective for young children
Nov. 4, 2022—A Vanderbilt study finds that Moderna’s COVID-19 vaccine is safe and effective in children 6 months to 5 years of age.
Event to spotlight VUMC’s COVID-19 research efforts
Nov. 3, 2022—The public is invited to listen in as scientists on the forefront of COVID-19 research at Vanderbilt University Medical Center share their personal stories on Wednesday afternoon, Nov. 16, in 214 Light Hall.
